Cargando…
SARS-CoV-2/COVID-19 – Epidemiologie und Prävention
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread globally since December 2019. A first wave is visible up to the end of June 2020 in many regions. This article presents a review of the current knowledge on the epidemiology and prevention. The SARS-CoV‑2 predominantly r...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736674/ https://www.ncbi.nlm.nih.gov/pubmed/33343742 http://dx.doi.org/10.1007/s11560-020-00472-0 |
_version_ | 1783622813416947712 |
---|---|
author | Salzberger, Bernd Buder, Felix Lampl, Benedikt Ehrenstein, Boris Hitzenbichler, Florian Holzmann, Thomas Schmidt, Barbara Hanses, Frank |
author_facet | Salzberger, Bernd Buder, Felix Lampl, Benedikt Ehrenstein, Boris Hitzenbichler, Florian Holzmann, Thomas Schmidt, Barbara Hanses, Frank |
author_sort | Salzberger, Bernd |
collection | PubMed |
description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread globally since December 2019. A first wave is visible up to the end of June 2020 in many regions. This article presents a review of the current knowledge on the epidemiology and prevention. The SARS-CoV‑2 predominantly replicates in the upper and lower respiratory tracts and is particularly transmitted by droplets and aerosols. The estimate for the basic reproduction number (R(0)) is between 2 and 3 and the median incubation period is 6 days (range 2–14 days). As with the related SARS-CoV and Middle East respiratory syndrome (MERS-CoV), superspreading events play an important role in the dissemination. A high proportion of infections are uncomplicated but moderate or severe courses develop in 5–10% of infected persons. Pneumonia, cardiac involvement and thromboembolisms are the most frequent manifestations leading to hospitalization. Risk factors for a complicated course are high age, hypertension, diabetes mellitus and chronic cardiovascular and pulmonary diseases as well as immunodeficiency. Currently, the estimation for the infection fatality rate (IFR) is between 0.5% and 1% across all age groups. Outbreaks were limited in many regions with bundles of various measures for reduction of social contacts. The incidence for the first wave in Germany can be estimated as 0.4–1.8% and excess mortality could not be observed. |
format | Online Article Text |
id | pubmed-7736674 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Medizin |
record_format | MEDLINE/PubMed |
spelling | pubmed-77366742020-12-15 SARS-CoV-2/COVID-19 – Epidemiologie und Prävention Salzberger, Bernd Buder, Felix Lampl, Benedikt Ehrenstein, Boris Hitzenbichler, Florian Holzmann, Thomas Schmidt, Barbara Hanses, Frank Nephrologe Leitthema Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread globally since December 2019. A first wave is visible up to the end of June 2020 in many regions. This article presents a review of the current knowledge on the epidemiology and prevention. The SARS-CoV‑2 predominantly replicates in the upper and lower respiratory tracts and is particularly transmitted by droplets and aerosols. The estimate for the basic reproduction number (R(0)) is between 2 and 3 and the median incubation period is 6 days (range 2–14 days). As with the related SARS-CoV and Middle East respiratory syndrome (MERS-CoV), superspreading events play an important role in the dissemination. A high proportion of infections are uncomplicated but moderate or severe courses develop in 5–10% of infected persons. Pneumonia, cardiac involvement and thromboembolisms are the most frequent manifestations leading to hospitalization. Risk factors for a complicated course are high age, hypertension, diabetes mellitus and chronic cardiovascular and pulmonary diseases as well as immunodeficiency. Currently, the estimation for the infection fatality rate (IFR) is between 0.5% and 1% across all age groups. Outbreaks were limited in many regions with bundles of various measures for reduction of social contacts. The incidence for the first wave in Germany can be estimated as 0.4–1.8% and excess mortality could not be observed. Springer Medizin 2020-12-15 2021 /pmc/articles/PMC7736674/ /pubmed/33343742 http://dx.doi.org/10.1007/s11560-020-00472-0 Text en © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Leitthema Salzberger, Bernd Buder, Felix Lampl, Benedikt Ehrenstein, Boris Hitzenbichler, Florian Holzmann, Thomas Schmidt, Barbara Hanses, Frank SARS-CoV-2/COVID-19 – Epidemiologie und Prävention |
title | SARS-CoV-2/COVID-19 – Epidemiologie und Prävention |
title_full | SARS-CoV-2/COVID-19 – Epidemiologie und Prävention |
title_fullStr | SARS-CoV-2/COVID-19 – Epidemiologie und Prävention |
title_full_unstemmed | SARS-CoV-2/COVID-19 – Epidemiologie und Prävention |
title_short | SARS-CoV-2/COVID-19 – Epidemiologie und Prävention |
title_sort | sars-cov-2/covid-19 – epidemiologie und prävention |
topic | Leitthema |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736674/ https://www.ncbi.nlm.nih.gov/pubmed/33343742 http://dx.doi.org/10.1007/s11560-020-00472-0 |
work_keys_str_mv | AT salzbergerbernd sarscov2covid19epidemiologieundpravention AT buderfelix sarscov2covid19epidemiologieundpravention AT lamplbenedikt sarscov2covid19epidemiologieundpravention AT ehrensteinboris sarscov2covid19epidemiologieundpravention AT hitzenbichlerflorian sarscov2covid19epidemiologieundpravention AT holzmannthomas sarscov2covid19epidemiologieundpravention AT schmidtbarbara sarscov2covid19epidemiologieundpravention AT hansesfrank sarscov2covid19epidemiologieundpravention |